Roche: Ocrevus approved in Switzerland.
(CercleFinance.com) - Roche has announced that the Swiss authority for the control and authorisation of therapeutic products (Swissmedic) has approved Ocrevus (ocrelizumab) for the treatment of adult patients with primary progressive and relapsing forms of multiple sclerosis.
"MS, which affects almost 15,000 people in Switzerland, is the leading cause of non-traumatic disability in young adults and often results in serious and permanent disabilities," said the Swiss health group.
This authorization in Switzerland is the first for Ocrevus in Europe, after those obtained in North and South America, the Middle East, Ukraine and Australia. Applications for licenses are currently being studied in 50 countries around the world.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
"MS, which affects almost 15,000 people in Switzerland, is the leading cause of non-traumatic disability in young adults and often results in serious and permanent disabilities," said the Swiss health group.
This authorization in Switzerland is the first for Ocrevus in Europe, after those obtained in North and South America, the Middle East, Ukraine and Australia. Applications for licenses are currently being studied in 50 countries around the world.
Copyright (c) 2017 CercleFinance.com. All rights reserved.